![ESMO23_20.10_GUProstate_Proffered_Audience](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/20.10.2023/esmo23_20.10_guprostate_proffered_audience/18320784-1-eng-GB/esmo23_20.10_guprostate_proffered_audience_i770.jpg)
Phase III data confirm that adjuvant radiotherapy has no benefit following radical prostatectomy
Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery